(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 July 2013 (25.07.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/109929 A1

(51) International Patent Classification:
C07H 1/08 (2006.01) *C12P 7/64* (2006.01)
C07H 3/06 (2006.01) *C11C 1/00* (2006.01)
A61K 31/7032 (2006.01)

(21) International Application Number:
PCT/US2013/022201

(22) International Filing Date:
18 January 2013 (18.01.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/588,882 20 January 2012 (20.01.2012) US

(71) Applicant: **GARNET BIOTHERAPEUTICS, INC.** [US/US]; 1 Great Valley Parkway, Suite 12, Malvern, PA 19355 (US).

(72) Inventors; and

(71) Applicants : **RAGAGLIA, Vanessa** [US/US]; 123 Spring Tree Drive, Newtown Square, PA 19073 (US). **SHARMA, Vandana, Madanlal** [IN/US]; 9801 Germantown Pike, Apt. 120, Lafayette Hill, PA 19444 (US).

(74) Agents: **GOLDSTEIN, Jorge, A.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue N.W, Washington, DC 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: METHODS OF GANGLIOSIDE PRODUCTION



FIG. 1

(57) Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1in cell culture are also provided.

WO 2013/109929 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*